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Abstract 
Objective: Use of laser therapy has most 
recently been introduced as a non-invasive 
option for the treatment of genitourinary 
syndrome of menopause (GSM). Recent 
literature has shown promise in providing benefit 
for patients with symptoms of vulvovaginal 
atrophy (VVA) and stress urinary incontinence 
with minimal adverse effects. Despite this, the 
United States Food and Drug Administration has 
not cleared laser therapy for these specific 
indications given the lack of sufficient evidence 
to support safety and efficacy. 
A case is presented of a patient with GSM in the 
setting of lichen sclerosus who was referred to a 
tertiary vulvovaginal disease clinic after 
worsening of symptoms after three laser therapy 
treatments. Patient data is protected by the 
Health Insurance Portability and Accountability 
Act of 1996. 
The case presented demonstrates initial 
worsening of symptoms after treatment with 
laser therapy, with initial exam findings showing 
atrophic vaginitis, marked introital narrowing, 
partial phimosis of the clitoral hood, and fusion 
of the labia minor and majora. The patient 
ultimately had complete resolution of post-laser 
therapy symptoms by one year after initial 
presentation. The case findings and follow-up 
are presented. 
Conclusions: Despite case series and studies 
in the literature showing promise of the use of 
laser therapy for GSM and urinary incontinence, 
laser therapy is not currently FDA-approved for 
these indications. Large scale, long-term 
prospective randomized controlled data is 
necessary to provide data on the safety, 
efficacy, indications, and appropriate candidates 
for laser therapy. 
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Introduction 
With an aging population in the United 
States, the genitourinary syndrome of 
menopause (GSM) is becoming more 
prevalent, with up to 40-80% of 
postmenopausal women affected1. GSM 
symptoms include decreased vaginal 
canal and introital caliber, decreased 
quality and elasticity of vaginal tissues, 
associated vaginal dryness, 
dyspareunia, and voiding dysfunction2. 
These symptoms describe a progressive 
condition related to a hypoestrogenic 
state of genitourinary tissues seen after 
menopause, during lactation, or 
associated with treatment for hormone-
dependent cancers. Current first-line 
therapies include vaginal moisturizers, 
topical or systemic estrogens, and Kegel 
exercises. Although estrogen therapy 
has proven benefit for GSM and vulvar 
vaginal atrophy (VVA), some patient 
populations may not be candidates3. 
Salvatore et al. demonstrated benefit of 
VVA symptoms with use of a fractional 
CO2 laser through connective tissue 
remodeling. The study showed 
improvements of vaginal burning, 
itching, and dyspareunia at a 12-week 
follow-up with subsequent 
improvements in sexual health and 
quality of life4.  
In addition to VVA, many 
postmenopausal females also suffer 
from lichen sclerosus, a benign, 
progressive dermatologic condition that 
affects the anogenital skin in the 
majority of cases. Vulvar lichen 
sclerosus (VLS) has a mean age of 
onset in the mid- to late-50s. Lichen 
sclerosus is marked by inflammation 
and epithelial thinning, leading to 
scarring and introital stenosis with 
subsequent impacts on quality of life. 
Additionally, VLS is a risk factor for 
vulvar intraepithelial neoplasia and 
squamous cell carcinoma, with lifetime 
risk estimated 2-6%5. Topical 
corticosteroids are the first-line therapy 
for VLS, although other topical 
immunosuppressive agents, including 
tacrolimus, and rarely systemic 
immunomodulating therapies have been 
described. 
Laser therapies are reported to be a 
minimally invasive treatment option, and 
their proposed mechanism includes the 
creation of small epithelial and lamina 
propria wounds via laser-generated heat 
for the supposed regeneration of 
tissues6. Studies have demonstrated 
that the new dermal collagen 
regeneration lasts at least 6 months 
after treatment7. In the treatment of 
GSM, two types of laser therapy are 
currently used: fractional micro-ablative 
infrared CO2 and non-ablative infrared 
lasers with an erbium-doped yttrium 
aluminum garnet medium (Er:YAG) 
lasers8. Histologic and gross 
examination of laser-treated 
vulvovaginal tissues has been shown to 
improve lubrication and tissue 
architecture, including rugae and 
superficial epithelium, resulting in tissue 
with qualities similar to estrogenized 
tissue9.  
Despite the touted benefits of laser 
therapy, at present, vulvovaginal CO2 
laser therapy is not approved by the 
United States Food and Drug 
Administration (FDA) for GSM, urinary 
incontinence, or lichen sclerosus 
indications. According to the FDA 
position statement, no guidelines exist 
regarding which patients should be 
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considered appropriate for this 
therapy10. In fact, in July 2018 the FDA 
warned against the use of these energy-
based devices for GSM and other 
vaginal rejuvenation/cosmetic purposes, 
citing adverse events including vaginal 
burns, scarring, and chronic pelvic pain 
11. The North American Menopause 
Society (NAMS) affirms, and states that 
while a promising emerging therapy, 
they call for more “randomized, 
prospective, sham-controlled trials of 
adequate size and scope”12. 
Additionally, the American College of 
Obstetricians and Gynecologists 
(ACOG) recommends that regarding 
vaginal cosmetic procedures, women 
must be informed that high-quality data 
about the safety, efficacy, and potential 
complications is lacking13.   
Here we present the case of a patient 
with GSM in the setting of chronic lichen 
sclerosus who sought care with CO2 
vaginal laser therapy.  
Case Presentation 
The case presented is a 65-year-old 
postmenopausal Caucasian female 
presenting to the vulvovaginal disease 
clinic at a tertiary care center for 
evaluation of dyspareunia, lower urinary 
tract symptoms, pelvic pain, and 
atrophic vaginitis. These symptoms 
developed three months after she 
received vaginal laser therapy with a 
fractional CO2 laser. Approximately 6 
years prior, in 2012, the patient had 
experienced a tragic personal loss and 
subsequently developed pelvic pain, 
difficulty voiding, and dyspareunia in the 
setting of existing lichen sclerosus. After 
receiving pelvic floor physical therapy, 
vaginal dilator therapy, and biofeedback 
therapy for several months, her 
symptoms became more manageable. 
Under the guidance of her gynecologist, 
she underwent laser therapy for vaginal 
dryness and dyspareunia in an effort to 
improve “vaginal tissue health” with a 
local urologist. She received three 
treatments in total from 12/1/2017 
through 3/28/2018, with her last 
treatment approximately three months 
prior to presentation for care. The 
patient noted that during the three 
treatments, she had worsening 
symptoms, including urge incontinence 
symptoms, voiding 20-25 times per day, 
nocturia 3-4 times nightly, and 
significant mid-void dysuria beginning 
after the first treatment. She also 
reported frequent vaginal itching and 
severe sharp pains during intercourse, 
which were not present prior to the laser 
treatments. She underwent cystoscopy 
with hydrodistension without 
improvement in symptoms. She also 
tried medical therapy with oxybutynin for 
urge incontinence without improvement. 
For her vaginal symptoms, she tried 
vaginal estrogen cream although opted 
to discontinue use secondary to external 
irritation before seeking subsequent 
evaluation.  
At her initial visit with the vulvovaginal 
disease clinic, her initial physical exam 
was remarkable for profound atrophic 
vaginitis with partial phimosis of the 
clitoral hood, and fusion of the anterior 
labia minora and majora. Her exam was 
notable for uniform hypopigmentation in 
a horseshoe distribution around the 
clitoris with associated loss of hair. 
There was severe introital narrowing, 
with ability to accommodate only one 
finger in diameter for examination. The 
levator ani muscles were tender to 
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palpation with high resting tone 
bilaterally, and the patient had 
significant discomfort on bimanual 
exam. Findings consistent with lichen 
sclerosus were identified as well (Image 
1).  
 
Image 1: Examination findings on 
initial presentation to vulvovaginal 
disease clinic 
Additionally, she did have a vaginal 
yeast culture positive for Candida 
albicans which was treated with 
fluconazole in addition to initial 
treatment including estradiol cream and 
hydrocortisone butyrate ointment. She 
had negative urine analysis findings. 
Similarly, to prior trials of topical 
estrogen, the patient was unable to 
tolerate either topical medication due to 
irritation, and she subsequently 
discontinued use of both estradiol and 
hydrocortisone ointments. She was 
ultimately started on a compounded 
vaginal estrogen cream that she 
tolerated. The patient was counseled on 
vulvovaginal skincare guidelines to 
minimize irritation and it was 
recommended that she also resume 
pelvic floor physical therapy, with the 
goal to increase vulvar comfort and to 
resume sexual activity. The patient was 
seen by the urology team at the tertiary 
hospital, who recommended mirabegron 
for her urge urinary incontinence.  
On follow-up three months later, the 
patient had much improved vulvar 
atrophy symptoms and improvement on 
exam with ability to tolerate small 
(circumference 2 inches) and medium-
sized (circumference 3.5 inches) 
dilators. On exam, the areas of 
hypopigmentation present initially were 
improved and although levator ani 
muscle tone remained elevated, the 
patient did not experience pain on 
palpation. Additionally, physical exam 
demonstrated decreased irritation at the 
posterior fourchette that was initially 
present on the first evaluation. Although 
the patient discontinued mirabegron, 
she continued working with her urologist 
and with pelvic floor physical therapy for 
treatment of urinary urgency (Image 2).  
 
Image 2: Examination findings at 
three-month follow-up 
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By five months after initial presentation, 
the patient was able to tolerate the 
largest dilator size (circumference 4 
inches) without discomfort. At her five-
month follow-up visit, she also reported 
much improved day-to-day symptoms, 
with decreased pain, irritation, and 
urinary symptoms overall (Image 3).  
 
Image 3: Examination findings at five-
month follow-up 
By one year after initial presentation she 
reported resumption of sexual activity 
with improvement of pain symptoms. 
She had intermittent cultures positive for 
vaginal yeast infection with Candida 
parapsilosis, for which she took 
fluconazole for treatment as needed. 
She additionally reported improvement 
of her urinary symptoms overall. The 
patient continued to be followed every 6 
months in the vulvovaginal disease 
clinic for monitoring of lichen sclerosus, 
given the 2-6% risk of vulvar cancer to 
develop in the setting of VLS. She was 
followed for atrophic vaginitis and 
history of yeast vulvovaginitis as well. 
 
Discussion 
Since the introduction of laser therapy, 
many specialties have adopted its use 
for a wide variety of treatments. Studies 
performed to analyze the benefit of laser 
therapy for GSM and stress urinary 
incontinence treatment have shown 
promise in the treatment of GSM 
symptoms. In 2014, a study of 77 
postmenopausal women with 
vulvovaginal atrophy used a 12-week (3 
month) treatment program of vaginal 
laser. Prior to the study, 20 of the 
women avoided intercourse secondary 
to pain. Of those, 17 (85%) reported 
regaining a “normal sex life” after 
treatment14. Additionally, a 2016 study 
of 30 women showed that 25 (83%) of 
the participants gained an increase in 
comfortable dilator size at 3-month 
follow up. The study also demonstrated 
statistically significant improvements in 
pain, burning, itching, dryness, and 
dyspareunia15. Recent studies have 
demonstrated promise of lasers in 
treatment of stress urinary incontinence. 
In 2017, a study of 161 postmenopausal 
women with GSM evaluated the effect of 
an ablative fractional CO2 laser as 
alternative treatment for stress urinary 
incontinence. The laser treatment group 
showed significant improvement in 
International Consultation on 
Incontinence Questionnaire-Urinary 
Incontinence Short Form (ICIQ-UI SF) 
scores and in 1-hour pad weight test at 
12 months, 24 months, and 36 
months16. Most recently, researchers 
conducted the first randomized 
controlled trial of 52 post-menopausal 
patients with biopsy-proven lichen 
sclerosus. Patients were randomized to 
receive either fractional CO2 laser 
treatment or clobetasol propionate for 6 
Proceedings in Obstetrics and Gynecology, 2020;10(1):12 
Laser therapy for vulvovaginal atrophy  6 
 
months. Findings of the study concluded 
that laser therapy for lichen sclerosus 
was “noninferior to steroid therapy six 
months” after assessment using various 
patient- and physician-based scores17.  
Despite these promising studies, 
however, laser therapy has not been 
cleared for these indications by the 
FDA, given the lack of large-scale and 
long-term evidence. Many of the studies 
currently in the literature have follow-up 
periods of 12 weeks, with few studies 
following patients to 12 months. 
Additionally, very little evidence exists 
on the indications, criteria for 
candidates, standardization of 
technique, or adverse event rate. 
Furthermore, the effects of laser therapy 
on surrounding pelvic organs, including 
the bladder, rectum, and pelvic nerves 
and vasculature, remain unknown. 
While there are case series and studies 
in the literature that provide evidence of 
the benefit for GSM and incontinence, 
many case reports also exist describing 
worsening symptoms related to scarring, 
fibrosis, and adhesions that result from 
laser therapy. Information on patient 
demographic variables, laser therapy 
technique and settings, and indications 
that are more likely to yield successful 
results remains scant.  
In the case discussed here, we present 
a 65-year-old postmenopausal 
Caucasian female who sought care for 
worsening pelvic pain and atrophic 
vaginitis in the setting of lichen 
sclerosus following treatment with laser 
therapy. This patient had complete 
resolution of symptoms one year after 
initial presentation. The patient’s 
atrophic vaginitis was complicated by 
lichen sclerosus, and she ultimately had 
resolution of atrophic symptoms after 
starting compounded estrogen cream. 
While laser therapy is currently studied 
for treatment of atrophic vaginitis and 
urinary incontinence, it is not  
considered adequate therapy for lichen 
sclerosus. Although topical steroid use 
is typically used in the management of 
lichen sclerosus, the patient was unable 
to tolerate a mid-potency topical steroid 
due to burning and irritation several 
hours after application. The mechanism 
through which this patient ultimately 
achieved symptom resolution remains 
unclear. It is possible that vulvovaginal 
laser therapy requires an initial period of 
symptom worsening during initial tissue 
injury, after which healing is ultimately 
achieved. It may be possible that 
patients need counseling on 
expectations of new, worsening 
symptoms before the end result is 
achieved. It may also be possible that 
the patient’s symptoms improved 
through the compounded vaginal 
estrogen, and that her initial external 
irritation with other topical vaginal forms 
worsened her symptoms following tissue 
injury generated by laser therapy. This 
patient had previously been unable to 
tolerate several forms of topical 
estrogen before eventually working with 
an allergist to find a vaginal estrogen 
form that was non-irritating, likely due to 
fewer preservatives in the base of the 
estrogen cream. Similarly, the patient’s 
intolerance of mid-potency steroid 
cream may be due to preservatives or 
other chemical irritants in the base.  
Conclusions 
The patient presented in this case 
suffered initial worsening of her 
symptoms as well as the addition of new 
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urinary symptoms during and shortly 
after completing three vaginal laser 
therapy treatments. Laser therapy is 
currently not FDA-approved for GSM, 
incontinence, or lichen sclerosus, and 
no standardized guidelines exist to 
guide clinicians on which patients might 
benefit from therapy, rates of 
complications, or standardized 
techniques for laser therapy. The 
current first-line therapy for atrophic 
vaginitis is topical estrogen cream, 
which is a treatment that is expensive 
and poorly reimbursed for this age 
group of patients in the United States. 
Additionally, topical estrogen cream 
requires frequent use for benefit, which 
contributes further to potential 
compliance issues.  
While the patient presented here had 
improvement, there are other case 
reports of patients harmed by laser 
treatments in recent years. Further large 
scale, prospective, randomized 
controlled trials are necessary to provide 
safety and efficacy data to guide use of 
this potentially promising treatment 
option. 
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